BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 9131587)

  • 1. A genetic approach to mapping the p53 binding site in the MDM2 protein.
    Freedman DA; Epstein CB; Roth JC; Levine AJ
    Mol Med; 1997 Apr; 3(4):248-59. PubMed ID: 9131587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A site-directed mutagenesis study of the MdmX RING domain.
    Egorova O; Mis M; Sheng Y
    Biochem Biophys Res Commun; 2014 May; 447(4):696-701. PubMed ID: 24755078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mdm2 RING mutation enhances p53 transcriptional activity and p53-p300 interaction.
    Clegg HV; Itahana Y; Itahana K; Ramalingam S; Zhang Y
    PLoS One; 2012; 7(5):e38212. PubMed ID: 22666487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-terminal 130 amino acids of MDM2 are sufficient to inhibit p53-mediated transcriptional activation.
    Leng P; Brown DR; Shivakumar CV; Deb S; Deb SP
    Oncogene; 1995 Apr; 10(7):1275-82. PubMed ID: 7731677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The tumor suppressor p53 and the oncoprotein simian virus 40 T antigen bind to overlapping domains on the MDM2 protein.
    Brown DR; Deb S; Muñoz RM; Subler MA; Deb SP
    Mol Cell Biol; 1993 Nov; 13(11):6849-57. PubMed ID: 8413278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural analysis of MDM2 RING separates degradation from regulation of p53 transcription activity.
    Nomura K; Klejnot M; Kowalczyk D; Hock AK; Sibbet GJ; Vousden KH; Huang DT
    Nat Struct Mol Biol; 2017 Jul; 24(7):578-587. PubMed ID: 28553961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer-associated mutations in the MDM2 zinc finger domain disrupt ribosomal protein interaction and attenuate MDM2-induced p53 degradation.
    Lindström MS; Jin A; Deisenroth C; White Wolf G; Zhang Y
    Mol Cell Biol; 2007 Feb; 27(3):1056-68. PubMed ID: 17116689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hdmx stabilizes Mdm2 and p53.
    Stad R; Ramos YF; Little N; Grivell S; Attema J; van Der Eb AJ; Jochemsen AG
    J Biol Chem; 2000 Sep; 275(36):28039-44. PubMed ID: 10827196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The conformationally flexible S9-S10 linker region in the core domain of p53 contains a novel MDM2 binding site whose mutation increases ubiquitination of p53 in vivo.
    Shimizu H; Burch LR; Smith AJ; Dornan D; Wallace M; Ball KL; Hupp TR
    J Biol Chem; 2002 Aug; 277(32):28446-58. PubMed ID: 11925449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MDM2 interacts with MDMX through their RING finger domains.
    Tanimura S; Ohtsuka S; Mitsui K; Shirouzu K; Yoshimura A; Ohtsubo M
    FEBS Lett; 1999 Mar; 447(1):5-9. PubMed ID: 10218570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functions of the MDM2 oncoprotein.
    Freedman DA; Wu L; Levine AJ
    Cell Mol Life Sci; 1999 Jan; 55(1):96-107. PubMed ID: 10065155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2.
    Unger T; Juven-Gershon T; Moallem E; Berger M; Vogt Sionov R; Lozano G; Oren M; Haupt Y
    EMBO J; 1999 Apr; 18(7):1805-14. PubMed ID: 10202144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus.
    Mayo LD; Donner DB
    Proc Natl Acad Sci U S A; 2001 Sep; 98(20):11598-603. PubMed ID: 11504915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo.
    Midgley CA; Desterro JM; Saville MK; Howard S; Sparks A; Hay RT; Lane DP
    Oncogene; 2000 May; 19(19):2312-23. PubMed ID: 10822382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biological significance of a small highly conserved region in the N terminus of the p53 tumour suppressor protein.
    Liu WL; Midgley C; Stephen C; Saville M; Lane DP
    J Mol Biol; 2001 Nov; 313(4):711-31. PubMed ID: 11697899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative study of the p53-mdm2 and p53-MDMX interfaces.
    Böttger V; Böttger A; Garcia-Echeverria C; Ramos YF; van der Eb AJ; Jochemsen AG; Lane DP
    Oncogene; 1999 Jan; 18(1):189-99. PubMed ID: 9926934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain.
    Kussie PH; Gorina S; Marechal V; Elenbaas B; Moreau J; Levine AJ; Pavletich NP
    Science; 1996 Nov; 274(5289):948-53. PubMed ID: 8875929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein.
    Martin K; Trouche D; Hagemeier C; Sørensen TS; La Thangue NB; Kouzarides T
    Nature; 1995 Jun; 375(6533):691-4. PubMed ID: 7791903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of p53 and MDM2 activity by MTBP.
    Brady M; Vlatkovic N; Boyd MT
    Mol Cell Biol; 2005 Jan; 25(2):545-53. PubMed ID: 15632057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypophosphorylation of Mdm2 augments p53 stability.
    Blattner C; Hay T; Meek DW; Lane DP
    Mol Cell Biol; 2002 Sep; 22(17):6170-82. PubMed ID: 12167711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.